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OBJECTIVES: MiRNAs are intrinsic RNAs that interfere with protein translation. Few studies on the synergistic
effects of miRNAs have been reported. Both miR-424 and miR-381 have been individually reported to be
involved in carcinogenesis. They share a common putative target, WEE1, which is described as an inhibitor of
G2/M progression. Here, we studied the synergistic effects of miR-424 and miR-381 on renal cancer cells.
METHODS: The viability of 786-O cells was analyzed after transfection with either a combination of miR-424
and miR-381 or each miRNA alone. We investigated cell cycle progression and apoptosis with flow cytometry.
To confirm apoptosis and the abrogation of G2/M arrest, we determined the level of pHH3, which is an
indicator of mitosis, and caspase-3/7 activity. The expression levels of WEE1, Cdc25, cH2AX, and Cdc2 were
manipulated to investigate the roles of these proteins in the miRNA-induced anti-tumor effects. To verify that
WEE1 was a direct target of both miR-424 and miR-381, we performed a dual luciferase reporter assay.
RESULTS: We showed that the combination of these miRNAs synergistically inhibited proliferation, abrogated
G2/M arrest, and induced apoptosis. This combination led to Cdc2 activation through WEE1 inhibition. This
regulation was more effective when cells were treated with both miRNAs than with either miRNA alone,
indicating synergy between these miRNAs. WEE1 was verified to be a direct target of each miRNA according to
the luciferase reporter assay.
CONCLUSIONS: These data clearly demonstrate that these two miRNAs might synergistically act as novel
modulators of tumorigenesis by down-regulating WEE1 expression in renal cell cancer cells.
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& INTRODUCTION
MiRNAs (miRs) are small endogenous RNAs that inter-
fere with protein translation by binding to target mRNAs
(1). MiRs can bind to the 3’ untranslated region (3’-UTR) of
their targets and silence gene expression in a sequence-
specific manner. The modulation of gene expression by
miRs is involved in the regulation of many crucial biological
events, such as apoptosis (2), cell cycle distribution (3),
cellular differentiation (4), and cellular proliferation (5). A
considerable body of evidence has confirmed that miRs play
roles as tumor suppressors. Moreover, miRs have emerged
as key regulators in renal cancer and may be potential
therapeutic targets (6).
The control of entry into mitosis is highly conserved in all
eukaryotic cells (7). The key mitotic inducer is the mitotic
cyclin-dependent kinase Cdc2, and its activity is controlled
by a reversible inhibitory phosphorylation event (8). This
phosphorylation of Cdc2 is catalyzed by WEE1, which
has been described as an inhibitor of G2/M transition
(9). WEE1 was recently reported to be a safeguard against
mitotic catastrophe in instances of sensitive cell division.
Accordingly, WEE1 overexpression causes G2 arrest by
promoting the inhibitory phosphorylation of cyclin-depen-
dent kinases (CDKs) (10). This regulation of CDKs by WEE1
has been confirmed in various cancer types, such as
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glioblastoma (11), lung carcinoma (12), and breast cancer
(13). These previous studies demonstrated that WEE1
depletion reduced carcinoma cell survival and was corre-
lated with better prognosis. WEE1 expression was further
correlated with survival in patients with mantle cell
lymphoma (14). Moreover, in tumors in which the G1
checkpoint is defective, the tumor cells are more sensitive to
the abrogation of the G2 checkpoint (15). Therefore, WEE1
has become an interesting target in the development of a
‘‘cell cycle G2 checkpoint abrogation’’ treatment strategy.
We used five algorithms in starBase (http://starbase.
sysu.edu.cn/(16)) to determine whether WEE1 is a target
of miR regulation in renal clear cell carcinoma. We
hypothesized that miRNA-424 and miRNA-381 might be
involved in WEE1 inactivation.
It was previously determined that miR-424 played a critical
role in the development of cervical carcinomas through its
modulation of Chk1, a cell cycle regulator; therefore, this miR
is also considered a prognostic indicator and an important
therapeutic target (17). MiR-424 has also been shown to be
involved in the VEGF and FGF signaling pathways by
modulating VEGFR2 and FGFR1, leading to downstream
effects on angiogenesis (18). Another study demonstrated
that miR-424 deregulation is involved in the pathogenesis of
CN-AML patients with NPM1 mutations (19). In addition,
miR-424 expression has been reported to distinguish cancers
from high-grade intraepithelial neoplasia in colon tissues,
which suggests that miR-424 may have considerable clinical
value in the early diagnosis of colorectal cancer (20). The
deregulation of miR-381 and its target ID1 contributes to the
metastasis of lung adenocarcinomas, and a novel regulatory
‘‘miR-381-/LRRC4-MEK/ERK/AKT’’ network has been
thoroughly elucidated in glioma (21). MiR-381 has also been
identified as an important serum marker that could
potentially help diagnose brain tumors and monitor their
response to therapy (21). Moreover, miRNA expression
profiling in renal cell carcinoma demonstrated that miR-381
was significantly down-regulated in tumors compared with
normal kidney tissue (22). Therefore, we believe that both
miR-424 and miR-381 play important suppressive roles in
renal cell carcinoma; however, their exact effect and
mechanism of action are unknown.
There have been an increasing number of studies investi-
gating the anti-tumor effect of miRs and their mechanism of
regulation. A majority of target genes are modulated by the
same miR. This finding raises the following question: why do
so many different miRs control the same targets? A potential
explanation is that various miRs act together more efficiently.
In the present study, we investigated the synergistic effect of
miR-381 and miR-424 on the proliferation and apoptosis of
786-O cells in vitro. We also investigated the mechanism
through which miR-381 and miR-424 act as novel and potent
inhibitors of WEE1 in 786-O cells.
& MATERIALS AND METHODS
Cell culture and miR transfections
Double-stranded miRNA mimics (miR-381 and miR-424)
were synthesized by Shanghai GenePharma Company in
China and stored at -20 C˚. They were transfected into cells
using Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA,
USA) according to the manufacturer’s protocol. A random
miR sequence (non-targeting oligonucleotide) (Genepharma,
Shanghai, China) was used as a negative control (miR-NC). A
transfection efficiency of approximately 80% was achieved
using 6-carboxyfluorescein-labeled miR. Cells were har-
vested for total RNA and protein extraction. A renal clear
cell carcinoma cell line (786-O) and a renal tubular epithelial
cell line (HK-2) were procured from ATCC (Mannassas, VA,
USA) and cultured in RPMI-1640 supplemented with 10%
FBS in an incubator at 5% CO2 and 37 C˚.
Cell survival and proliferation---MTT assay
786-O cells were plated in a 96-well flat-bottomed plate.
They were transfected with miR-NC, miR-381, and miR-424
and incubated for 24 h, 48 h, or 72 h before adding MTT.
The cells were subsequently incubated for an additional 4 h
at 37 C˚ and 5% CO2. The absorbance at 540 nm was
determined, and the cell viability was defined as the
percentage of untreated cells.
Assessment of caspase 3/7 activity
Caspase-3/7 activity was evaluated using a caspase-3/7
assay (Promega, Madison, WI, USA). Cells (16105 cells per
well) were plated in a 96-well plate and incubated at 37 C˚
overnight. The cells were lysed after treatment with miR-381
and miR-424. The caspase-3/7 reagent (100 ml/well) was
added, and the plates were examined using a plate-reading
luminometer (Bio-Rad, Hercules, CA, USA) at an excitation
wavelength range of 485¡20 nm and an emission wave-
length range of 530¡25 nm.
Mitotic index
The 786-O cells were stained with DAPI (Auragene
Bioscience, Changsha, Hunan, China). We assessed mitotic
morphology according to duplicated chromatid pairs, which
align during cell division. The mitotic index of 786-O cells
was determined using the following formula: mitotic index
% = (number of mitotic cells/total number of cells)6100.
Cell cycle analysis
Following treatment with miR-381 and miR-424 for 48 h,
logarithmically growing cells were harvested and fixed with
70% ethanol at 4 C˚ overnight. After extensive washing with
PBS, the cells were suspended in Hank’s balanced salt
solution containing 75 mg/ml RNase A and 50 mg/ml
propidium iodide (Sigma, St.Louis, MO, USA). The cells
were incubated for 0.5 h at 37 C˚ before immediate analysis
using a FACS Canto II instrument (BD, San Jose, CA, USA).
They were further analyzed using the ModFit 2.0 cell cycle
analysis program (BD, San Jose, CA, USA).
Apoptosis Assay
An Annexin V/FITC apoptosis detection kit was pur-
chased from BD Biosciences (BD, San Jose, CA, USA). 786-O
cells were treated with miR-381 and miR-424 in 24-well
culture plates for 48 h. The cells were trypsinized and
centrifuged at 2500 g for 5 min, followed by resuspension in
buffer. Annexin V-FITC solution (Key Gene, JiangSu,
Nanjing, China) and PI (Sigma, St.Louis, MO, USA) were
added, and the cells were analyzed using a FACS Canto II
instrument (BD, San Jose, CA, USA).
Prediction of modulated miRs targeting WEE1
To identify miRs that target WEE1, we used five
algorithms to computationally predict potential modulated
miRs. The miRs were predicted using the starBase (16)
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database, which combines gene predictions from the
TargetScan, PicTar, RNA22, PITA, and miRanda algorithms.
Only targets that were predicted by at least three algorithms
were included. Potential miRs were chosen based on their
possible functions, the number of predicted target sites, and
target prediction by multiple algorithms.
RT-PCR and Western blotting
Total RNA was extracted with TRIzol reagent (Invitrogen,
Carlsbad, CA, USA), and its purity was determined at
260 nm. cDNA was synthesized through reverse transcrip-
tion using ReverTra Ace (Toyobo, Osaka, Japan). WEE1
primers were purchased from Sangon (Shanghai, China),
and the SYBR Green PCR Master Mix (YRBIO, Changsha,
Hunan, China) was used for RT-PCR. The reaction volume
was 20 ml, and PCR was performed in triplicate. Gene
expression was quantified using the comparative Ct method
(the DDCt method). 786-O cells were harvested for the
analysis of protein expression 48 h after treatment, followed
by Western blotting as previously described. Antibodies
against WEE1, Cdc25, MYT1, PARP, Bcl-2, and cH2AX were
obtained from Cell Signaling Technology (Danvers, MA,
USA). Antibodies against Cdc2 and p-Cdc2 were obtained
from Abcam (Cambridge, MA, USA). The histone H3 ps10
antibody was purchased from Millipore (Billerica, MA,
USA). b-Actin (Santa Cruz, California, USA) was used as an
internal control.
Validation of WEE1 as a target of miR-424 and miR-
381 using a luciferase reporter assay
WEE1 was predicted to be regulated by both miR-424 and
miR-381 using a miR target prediction tool (starBase). We
cloned the 3’-UTR of WEE1, which contained the putative
binding sites of miR-424 and miR-381, into an empty
luciferase reporter vector, pGL4.13 (Promega, Madison,
WI, USA). Mutations were introduced into the seed region
of miR-424 or miR-381 in the 3’-UTR of WEE1, and the
mutants were termed WEE1-3’-UTR-mut-1, WEE1-3’-UTR-
mut-2, WEE1-3’-UTR-mut-3, and WEE1-3’-UTR-mut-4. The
sequences of the constructs were verified with DNA
sequencing. 786-O cells seeded in 24-well plates were
transfected with the reporter plasmid and miR mimics or
a NC oligo using Lipofectamine 2000 (Invitrogen, Carlsbad,
CA, USA). Lysates were collected 48 h after transfection.
The luciferase activity was measured using a TD 20/20
luminometer (Promega, Madison, WI, USA) according to
the manufacturer’s protocol. The luminescence intensity of
firefly luciferase was normalized to that of renilla luciferase.
Statistical analysis
Data analysis was performed with SPSS 17.0 software
(SPSS Inc., Chicago, IL). Numerical values were expressed
as the mean ¡ SEM. The significance of inter-group
differences was evaluated with a one-way analysis of
variance, and the significance of single comparisons was
determined with Student’s t-test. All tests performed were
two sided. A p-value less than 0.05 was considered to be
statistically significant.
Ethics
Ethical approval for this investigation was obtained from
the Research Ethics Committee, Third Xiang-Ya Hospital of
Central South University.
& RESULTS
The levels of both miR-424 and miR-381 were decreased
in 786-O cells, and simultaneous transfection with both
miRs inhibited the proliferation of 786-O cells more
efficiently than transfection with either miR alone in vitro.
We determined the expression levels of miR-424 and miR-
381 using real-time PCR. We demonstrated a significantly
lower level of miR-424 (approximately 10-fold) in 786-O
cells compared with HK-2 cells, and miR-381 showed
similar results (3.7-fold) (Figure 1C). To assess the effects
of these two miRs on 786-O survival, we determined cell
viability following combined transfection or transfection
with either miR alone. Cell survival was assessed after
incubation for 24 h, 48 h, and 72 h. There was an obvious
inhibition of proliferation by approximately 4-fold after the
combined transfection of the two miRs, whereas either miR
alone had less influence on the survival of 786-O cells
(Figure 1 A). Cell death reached a maximum at 48 h after
transfection, and there was no significant increase in cell
death at 72 h compared with 48 h. To ascertain whether the
two miRs inhibited normal cells, the survival of HK-2 was
assessed using a similar MTT assay. In contrast to 786-O
cells, no inhibitory effect was observed in HK-2 cells
(Figure 1B). These data indicate that the combination of
miR-381 and miR-424 was effective in inhibiting the
proliferation of 786-O cells. Treatment with the combination
of miR-381 and miR-424 promoted mitotic entry and
induced apoptosis.
To confirm that the combination of the two miRs induced
mitotic entry, the mitotic index following combined trans-
fection was determined and compared with the transfection
of either miR alone. The number of mitotic cells was
significantly higher for 786-O cells treated with the
combination of the two miRs (Figure 2A). The percentage
of cells in mitosis following combined transfection was
approximately 5%, compared with 1.5%, 1.9%, and 2.0% in
the other three groups (Figure 2A). To investigate how
mitotic entry was modulated by combined treatment, 786-O
cells treated with both miR-424 and miR-381 for 48 h were
examined to assess the activation status of Cdc2. Upon co-
inhibition with miR-424 and miR-381, Cdc2 was unpho-
sphorylated (Figure 2C, lane 2). The subsequent activation
of Cdc2 resulted in a higher percentage of mitotic cells,
which reached as high as 5%, in cells treated with both miRs
compared with cells treated with either miR alone
(Figure 2A). Phospho-histone H3 (pHH3) is considered a
reliable biomarker of the mitotic count (23). The combina-
tion of both miRs led to an increased pHH3 level (Figure 2C,
lane 3), which reaches a maximum during mitosis and
reflects premature mitotic entry (24). These data indicate
that the two miRs modulated Cdc2 activation and augmen-
ted mitotic entry by inhibiting Cdc2 phosphorylation.
To evaluate the synergistic effect of these miRs on
apoptosis, cells were analyzed with flow cytometry follow-
ing labeling with Annexin V-FITC and PI. The combination
of miR-381 and miR-424 augmented the percentage of
apoptotic 786-O cells significantly more than monotherapy
(Figure 2D, E). This finding was confirmed through the
analysis of the apoptosis-related protein Bcl-2 (Figure 2C,
lane 5). As shown in Figure 2B, when 786-O cells were
treated with the combination of miRs for 48 h, there was a
significant decrease in caspase-3/7 activity, suggesting that
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this combination may result in synergistic cytotoxicity
through the activation of the caspase pathway.
The combination of miR-381 and miR-424 inhibited Cdc2
phosphorylation at Tyr15 by inhibiting WEE1, thereby
abrogating the G2/M block.
It has been reported that Cdc2/cyclin B kinase is activated
prior to the onset of mitotic entry, which could trigger G2/
M transition (25). It has been clearly established that in
addition to multiple mutations, endogenous DNA damage
is accumulated in the majority of carcinomas. WEE1 is
crucial for coordinating the DNA damage response and
genomic replication and for avoiding mitotic catastrophe
caused by the abrogation of G2 checkpoint arrest (26). Thus,
miR-381 and miR-424, putative regulators of WEE1, are vital
for the fate of 786-O cells. We therefore transfected 786-O
cells with a combination of miR-381 and miR-424 to test
whether G2/M arrest was abrogated. Accordingly, flow
cytometry results showed that G2/M arrest was abrogated
when 786-O cells were pretreated with both miRs for 48 h
but not when the cells were treated with either one alone
(Figures 3A and B). Treatment with miR-424 and miR-381
resulted in an obvious down-regulation of G2/M-arrested
cells, which accounted for approximately 3% of cells.
Neither miR-424 nor miR-381 led to a significant decrease
in the percentage of cells arrested in G2. The percentages of
cells arrested in G2 by miR-424 and miR-381 alone were 14%
and 13%, respectively (Figures 3A and B). Therefore, it is
clear that the simultaneous transfection of miR-381 and
miR-424 abrogated G2 arrest in 786-O cells.
To explore the molecular mechanisms underlying the
abrogation of G2/M cell cycle arrest induced by miR-381
and miR-424, we determined the expression levels of WEE1.
Figure 3C shows that there was a marked decrease in WEE1
activity following the transfection of 786-O cells with a
combination of miR-381 and miR-424 compared with the
control. As described above, Western blotting also demon-
strated that p-Cdc2 expression was decreased.
Thus, the above data suggest that the combined treatment
results in the synergistic inhibition of WEE1 and the
abrogation of the G2/M block, which are related to the
persistent inhibitory effect of WEE1 and Cdc2 activation.
We next determined whether miR-381 and miR-424
directly target WEE1, which in turn regulates the cell cycle
progression and apoptosis of 786-O cells. A bioinformatics
search (http://starbase.sysu.edu.cn) (16) revealed that the
3’-UTR of WEE1 (Figures 4A and B) was complementary to
the nucleotide bases of miR-424 and miR-381, which might
be involved in WEE1 inactivation.
To determine whether miR-424 and miR-381 act directly
on the WEE1 3’-UTR, we constructed a luciferase reporter
containing either the wild-type or a mutant WEE1 3’-UTR
(Figures 4A and B). The increased levels of miR-424 and
miR-381 following transfection were confirmed with real-
time PCR (Figure 4E) and significantly affected the
relative luciferase activity (Figures 4C and D). The results
revealed a statistically significant down-regulation of
luciferase activity when these cells were simultaneously
transfected with both miRs and 3’-UTR-WEE1-wt.
However, this regulation was significantly alleviated
when four nucleotides in the seed region were mutated
(Figures 4A and B), indicating that both miRs directly
regulate WEE1 together.
To provide further evidence that WEE1 down-regulation
is induced by both miRs, we transfected 786-O cells with
another mutant of the 3’-UTR of WEE1 and either miR. A
similar decrease in luciferase activity was observed
(Figures 4C and D). In addition, WEE1 expression decreased
significantly following transfection with either miR. Thus,
these data clearly show that miR-381 and miR-424 up-
regulation could induce WEE1 inhibition.
& DISCUSSION
A recent study demonstrated that miR-424 up-regulation
induced the inhibition and phosphorylation of Chk1, which
in turn modulated WEE1 and Cdc25c phosphorylation (17).
The activated WEE1 and inactivated Cdc25c coordinay
prevented Cdc2/cyclin B activation and mitotic entry in
Figure 1 -MiR-424 and miR-381 are poorly expressed in 786-O cells, and the combination of miR-424 and miR-381 significantly inhibited
the proliferation of 786-O cells. (A) Cell survival curves of 786-O cells treated with a combination of miR-424 and miR-381 and with
either miR alone. The lines represent three independent experiments, which were performed in triplicate. Synergistic inhibition was
significant in 786-O cells, and cell survival was decreased by approximately 4-fold compared with the control (p,0.01). (B) No similar
effects were observed in the normal cell line HK-2. (C) Both miRs (miR-424 and miR-381) were analyzed with real-time PCR using total
RNA from 786-O and HK-2 cells. We calculated DCt (miR Ct-U6 Ct) from the Ct values of each gene for normalization. The DCt values
were then converted into relative gene expression levels using the 22DDCt method. The graph shows the relative fold difference in
gene expression between 786-O and HK-2 cells. **p,0.01.
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Figure 2 -MiR-381 andmiR-424 synergistically promotedmitotic entry and induced apoptosis. (A) Themitotic index (%)was determined in
both 786-O cells and HK-2 cells. The combination of miRs significantly increased the mitotic index. (B) Cell death was analyzed through
caspase-3/7 activation in cells treatedwithmiR-424,miR-381, the combination, or DMSO for 48 h. Caspase 3/7 activity increased only in the
presence of both miRs comparedwith the control. (C) Cell lysates collected from control cells and cells treatedwithmiR-424, miR-381, and
the combination of miR-381 and miR-424 were assessed with SDS-PAGE. The combined treatment strongly reduced the level of p-Cdc2,
increased the level of pHH3, and increased the percentage of mitotic cells without DNA damage repair, which causedmitotic catastrophe
and apoptosis. The combination of miRs also down-regulated Bcl-2 expression compared with the control cells. b-Actin was used as a
loading control. (D) and (E) The fraction of apoptotic 786-O cells was investigated after the cells were stained with both Annexin V-FITC
and PI. (D) The means¡ SDs of three independent experiments. (E) Representative results. *p,0.05, **p,0.01.
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cancer cells (27). However, we observed different results
following the treatment of 786-O cells with miR-424 or miR-
381 alone; we showed that either miR alone had no marked
effect on 786-O cells. The regulatory effects of miRs on
apoptosis and proliferation have been clearly validated in
many reports, which demonstrate the targeting of various
cell cycle regulatory proteins by miRs (28). Moreover,
convincing evidence has shown that WEE1 inhibitors
synergize to achieve tumor regression (29). These observa-
tions led to the original hypothesis that the synergistic
inhibition of WEE1 could limit the repair of endogenous
DNA damage and therefore sensitize cancer cells to this
damage. WEE1 is considered the putative target of both
miR-424 and miR-381 according to the combination of gene
predictions from the miRBase, TargetScan, miRanda,
RNA22, and PicTar algorithms. We demonstrated that these
two miRs function synergistically to inhibit WEE1, and this
inhibition has an enhanced anti-tumor effect by modulating
Cdc2/cyclin B activity.
Our research showed that the combination of miR-424
and miR-381, which is also involved in the pathogenesis and
the drug resistance of leukemia (19), potentiated the anti-
tumor effect of each miR. The up-regulation of miR-424 was
also previously shown to inhibit the proliferation and cord
formation of endothelial cells by targeting VEGF and VEGF
receptor-2 in vitro (18). Interestingly, miR-424 has also been
previously investigated to determine its role in cell cycle
regulation. The expression of miR-424 was shown to block
cell cycle progression. When miR-424 was combined with
miR-503, additional effects were observed. We similarly
demonstrated that miR-424 combined with miR-381 could
augment the apoptosis of 786-O cells and directly affect cell
cycle progression by targeting WEE1. Thus, miR-424 and
miR-381 could be novel therapeutic targets for a majority of
individuals with renal carcinomas.
The Cdc2/cyclin B complex undergoes inhibitory phos-
phorylation by WEE1 and myelin transcription factor 1
(MYT1). In contrast, Cdc25 activates this complex through
dephosphorylation. Thus, WEE1, MYT1, and their counter-
part Cdc25 coordinate to regulate the activity of the Cdc2/
cyclin B complex and constitute the main switch for mitosis
(29). In this study, neither Cdc25 nor MYT1 was activated or
inhibited (Figure 3C), further confirming that the deregula-
tion of Cdc2 activity was induced by the synergistic effect of
both miRs on the WEE1/Cdc2 pathway (29).
In addition, the siRNA-mediated depletion of WEE1
augments DNA damage during cell cycle progression (30).
Recent studies have demonstrated that the WEE1 3’-UTR is
a direct target of miR-195, miR-128a, miR-155, and miR-516
(31). The results of our study support our hypothesis that a
post-translational mechanism involving miR-424 and miR-
381 may attenuate WEE1 expression. We demonstrated that
these two miRs interacted directly with the WEE1 3’-UTR.
As recent publications have highlighted, many genes
have multiple binding sites for many miRs. Therefore,
various combinations of miRs might overcome the relative
weakness of each individual miR (32). Further validation of
other predicted targets is being performed, and this analysis
may yield a more complex explanation for the interaction
between miR-424 and miR-381. We believe that an interac-
tion between miR-381 and miR-424 may help strengthen the
association between the two miRs and the WEE1 3’-UTR.
Neither miR-424 nor miR-381 alone significantly killed
human tumor cells. One possible explanation for the
synergistic effect is that each miR has unique targets in
addition to WEE1 (17,18). When combined, their unique
mRNA targets are able to enhance the binding effect of each
miR with WEE1, which was demonstrated previously (33).
Moreover, consistent with the synergistic effect of these two
miRs, the binding site proximity of miR-424 and miR-381
may be a crucial factor in the regulation of WEE1, which
potentially inhibits protein translation. Third, WEE1 plays
important roles in DNA duplication, chromosome conden-
sation, and anaphase entry (9,10). The explanation for the
synergistic inhibition may lie in any of these effects. Few
studies have investigated the synergistic inhibition of
cancers by miRs, and the various mechanisms need to be
further investigated (34). We currently have no definitive
explanation for the observed synergistic effect. Determining
the mechanism will require additional experiments that
Figure 3 - (A) and (B) Cell cycle progression was analyzed with FACS. Cells were treated with miR-381, miR-424, or the combination of
miR-381 and miR-424. Based on the DNA contents of the cells, the percentage of cells in G2/M decreased significantly after the
combination treatment compared with the control. (B) Representative results. (C) The combination of miR-381 and miR-424 abolished
the phosphorylation of Cdc2 at Tyr15. Both MYT1 and Cdc25 were ruled out in the regulation of this phosphorylation event. The cells
were treated as described above. **p,0.01.
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Figure 4 - (A) An illustration depicting the base pairing between miR-381 and the 3’-UTR of WEE1. Mutations in the 3’-UTR of WEE1
were designed for the first four consecutive bases (UAUA to AUAU) or the last four bases (CUUG to GAAC), generating two mutants
termed mutant-WEE1 3’-UTR-1 and mutant-WEE1 3’-UTR-2, respectively. (B) The base pairing between miR-424 and the 3’-UTR of WEE1
is shown. Similar to mutant 3’-UTR WEE1-1, mutant-WEE1 3’-UTR-3 and mutant-WEE1 3’-UTR-4 were designed according to the base
pairing between miR-424 and the 3’-UTR of WEE1. (C) and (D) Dual-luciferase reporter gene assay. 786-O cells were co-transfected with
the indicated reporter constructs and Renilla luciferase plasmids. The cells were also transfected with miR-NC, miR-381 mimic, or miR-
424 mimic. Forty-eight hours later, the luciferase activity was determined. The relative activity was normalized to the Renilla luciferase
activity. Significant differences in the luciferase activity are shown. (E) The increased expression levels of miR-424 and miR-381 upon
transfection were confirmed with real-time PCR. Western blotting showed that WEE1 was inhibited by both miR-424 and miR-381.
**p,0.01.
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were beyond the scope of this study. Clearly, further
research should be performed until this surprising biologi-
cal phenomenon is fully understood.
Our study demonstrated that carcinoma cells were more
susceptible to the combined miRs than normal cells. It is
therefore crucial to further validate this biological phenom-
enon and identify a significant therapeutic target. It was also
reported that the inhibition of WEE1 activity combined with
DNA damage resulted in increased cytotoxicity in p53-
deficient cells (30). Therefore, we will benefit from further
studies demonstrating a similar p53 status-dependent
mechanism for the effects of the combined treatment.
Various studies have shown that WEE1 depletion leads
to S phase block, increased apoptotic morphology, and
caspase-induced apoptosis (13,29). We also observed cas-
pase-induced apoptosis after combination treatment in 786-
O cells. The mechanism underlying caspase activation and
subsequent apoptosis is unknown. Further study is needed
to determine the mechanism through which miR-424 and
miR-381 synergistically induce caspase activation.
Few studies have been performed to assess the synergistic
effects of miRs, and thus, it is important to investigate new
combination treatment methods. We confirmed that miR-
424 in combination with miR-381 inhibited cell proliferation
and induced apoptosis in a synergistic manner. Our data
suggest that combining miR-381 and miR-424 may provide
therapeutic benefits to patients. This synergy may increase
the response rate and provide a clinical opportunity to
achieve anti-tumor effects.
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